Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
February 21st 2025Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
February 14th 2025Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.
Perspectives on the Usefulness of Real-world Data
February 14th 2025Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.
Safety Profile of New Therapies
February 7th 2025Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.
Outcomes with Raricimab and Choosing Between the New Therapies
February 7th 2025Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
January 31st 2025Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Patient Selection for Aflibercept 8 mg
January 31st 2025Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Adverse Events of the Port Delivery System and Addressing Challenges With Adoption
January 31st 2025Panelists discuss how careful patient selection and management of potential complications - including surgical risks, device-related adverse events, and cost-benefit considerations requiring operating room resources - are crucial factors in successfully implementing the port delivery system in clinical practice.
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
January 29th 2025Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.